Sinclair Pharma PLC Disclosure under Rule 2.10(c) (4056E)
18 Outubro 2018 - 3:01AM
UK Regulatory
TIDMSPH
RNS Number : 4056E
Sinclair Pharma PLC
18 October 2018
Toscafund Asset Management LLP
Disclosure under Rule 2.10(c) of The City Code on Takeovers and
Mergers
Toscafund Asset Management LLP ("Toscafund") provided a
non-binding letter of intent to Huadong Medicine Aesthetics
Investment (Hong Kong) Limited on 28 August 2018 regarding the
proposed acquisition of Sinclair Pharma plc ("Sinclair") as
referred to in the announcement of the recommended cash offer on 18
September 2018.
The non-binding letter of intent was for 148,613,603 ordinary
shares of 1p each in Sinclair Pharma plc.
On 16 October 2018 Sinclair announced that following a disposal,
Toscafund no longer intended to comply with the letter of intent in
respect of 92,000,000 ordinary shares of 1p each in Sinclair Pharma
plc.
In accordance with Rule 2.10(c) of The City Code on Takeovers
and Mergers it is today confirmed that following a further disposal
of 56,613,603 ordinary shares of 1p each in Sinclair Pharma plc
Toscafund no longer intends to comply with the letter of intent in
respect of any ordinary shares of 1p each in Sinclair Pharma
plc.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGGGMWUUPRGRM
(END) Dow Jones Newswires
October 18, 2018 02:00 ET (06:00 GMT)
Sinclair Pharma (LSE:SPH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Sinclair Pharma (LSE:SPH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Sinclair Pha da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Sinclair Pha